- Abstract viewed - 2751 times
- PDF downloaded - 1510 times
License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright
© Medicine and Pharmacy Reports, 2019
Affiliations
Minodora Desmirean
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
Dalma Deak
Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
Ioana Rus
Department of Hematology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania.
Delia Dima
Department of Hematology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania.
Sabina Iluta
Department of Hematology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania
Alexandra Preda
Department of Medical Oncology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania
Tiberiu Modovan
Department of Medical Oncology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania
Andrei Roman
Department of Radiology, Ion Chiricuta Oncology Institute Cluj Napoca, Romania
Ciprian Tomuleasa
Department of Hematology - Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca
Bobe Petrushev
Department of Pathology, Octavian Fodor Regional Institute of Gastroenterology and Hematology, Cluj Napoca, Romania
How to Cite
Paraneoplastic hypereosinophilia in a patient with peripheral T cell lymphoma, not otherwise specified
Abstract
Under normal physiological conditions, the bone marrow (BM) will have between 1% and 6% eosinophils, translating into a peripheral count of 0.05 – 0.5 x109 /L eosinophils in the blood smear. This process is coordinated by transcription factors with specific roles in differentiation and activation. Secondary eosinophilia may be a paraneoplastic syndrome, related to the presence of a subsequent malignancy, as presented in this case report. Such paraneoplastic manifestations should be addressed properly in order for the patient to receive the best treatment of choice. Even if eosinophilia was associated with B-cell malignancies before, this is a report associating this symptom to a peripheral T-cell lymphoma, not other specified, thus emphasizing the importance of a complex approach for the management of the oncological patient.